{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-001422","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.425280+00:00","generated_at":"2026-05-31T09:36:47.795199+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024","bullets":["Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.","Net loss $5.3M vs $6.5M YoY; R&D expense $3.5M (-9% YoY), G&A $2.2M (-31% YoY).","FDA cleared IND for NPM-119 (six-month GLP-1 implant for type 2 diabetes) in June 2024.","First-in-human LIBERATE-1 study for NPM-115 (obesity implant) expected to start Q4 2024 in Australia, data in 2025.","Veterinary GLP-1 implant data published in BMC Veterinary Research; 40% of domestic cats overweight."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-001422","json":"https://secwatch.observer/filing/0001753926-24-001422.json","markdown":"https://secwatch.observer/filing/0001753926-24-001422.md","text":"https://secwatch.observer/filing/0001753926-24-001422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/0001753926-24-001422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/vani-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:36:47.795199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}